ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3065-Fitzroy-St-Vincent-s-Hospital-Melbourne
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
43
trial(s) found.
NCT06943872
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
2024-517131-52-00--BGB-11417-303
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06801834
Advanced
Phase 3
Recruiting
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC) (
EVOKE-SCLC-04
)
anti-Trop2 antibody-drug conjugate
Small-cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06679101
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (
DREAMM-10
)
anti-BCMA-immunoconjugate
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
NCT06635824
Advanced
Phase 3
Recruiting
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) (
GCT1046-06
)
anti-PD-1 monoclonal antibody
taxane
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4215 - Southport - Gold Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06630806
Haem
Phase 1
Recruiting
A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
U1111-1301-4016--TED18162
)
anti-GPRC5D monoclonal antibody
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT06532006
Advanced
Phase 3
Recruiting
A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer (
HLX22-GC-301
)
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Cancer
Gastric cancer
HER2-positive gastric cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT06422520
Advanced
Phase 1
Recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors (
BGB-C354-101
)
anti-B7H3 antibody-drug conjugate
anti-PD-1 monoclonal antibody
Solid tumour
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - One Clinical Research
NCT06417814
Advanced
Phase 3
Recruiting
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (
TROPION-Lung15
)
EGFR inhibitor,third generation
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06388733
Advanced
Phase 3
Recruiting
A Phase 3, Open-label, Randomized 2-arm Study Comparing the Clinical Efficacy and Safety of Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma (
IVY-P3-24-021
)
PARP inhibitor
alkylating agent
Central nervous system cancer
Glioblastoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT06318273
Advanced
Phase 1
Recruiting
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer (
M24-742
)
anti-PSMA∕STEAP1 antibody-drug conjugate
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
NCT06297226
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (
QUINTESSENTIAL
)
autologous CAR-T cell therapy,GPRC5D-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06290505
Radonc
Phase 2
Recruiting
PALEO
: Phase II Clinical Trial of Chemoradioimmunotherapy for the ALleviation of oEsOphageal Cancer Complications
Carboplatin
Durvalumab
Paclitaxel
Radiotherapy
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
platinum-based antineoplastic agent
taxane
Oesophageal cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06184035
Radonc
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, Dose Escalation and Dose Expansion, First-in-human, Open-label, Multicenter, Single-arm Study Evaluating the Safety, Tolerability, Dosimetry, and Early Efficacy of [177Lu]Lu-SN201 in Participants With Progressive or Treatment-refractory Locally Advanced Unresectable, Metastatic or Recurrent Solid Tumors (
Tumorad
)
177Lu-SN201
cancer therapy
nanoparticle radiopharmaceutics
radiopharmaceutics
Cancer
Solid tumour
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06161441
Advanced
Phase 2
Recruiting
A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC (
R3767-ONC-2266
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06158841
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) (
CERVINO
)
Bortezomib
Carfilzomib
Dexamethasone
Elotuzumab
Pomalidomide
Selinexor
XPO1 inhibitor
anti-CS1 monoclonal antibody
cancer therapy
cancer therapy,CS1-targeting
cancer therapy,XPO1-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon modulator
glucocorticoid
immuno-oncology therapy,CS1-targeting
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06127407
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen (
CHONQUER
)
IDH1 R132 inhibitor
placebo
Chondrosarcoma
NOT Dedifferentiated chondrosarcoma
NOT Mesenchymal chondrosarcoma
NOT Myxoid chondrosarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06119581
Advanced
Phase 3
Recruiting
SUNRAY-01
, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
antimetabolite
placebo
Non-small cell lung cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06083207
Haem
Phase 1
Recruiting
A Phase I/II, Multicenter, Open-label, First-in-human Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma (
CIBI3003A101
)
bispecific T-cell engager,GPRC5D-targeting
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06077760
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (
INTerpath-002
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
placebo
Non-small cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (COMPLETED)
NCT05984277
Advanced
Phase 3
Recruiting
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC). (
eVOLVE-Lung02
)
anti-PD-1 monoclonal antibody
bispecific PD-L1/CTLA4 antibody
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT05952557
Curative
Phase 3
Recruiting
CAMBRIA-2
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
selective estrogen receptor degrader
selective estrogen receptor modulator
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
2576 - Bowral - Southern Highlands Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3677 - Wangaratta - Northeast Health Wangaratta
3844 - Traralgon - Latrobe Regional Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT05952037
Haem
Phase 2
Recruiting
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia (
U1111-1291-4524--BGB-11417-203
)
BTK inhibitor
Bcl2 inhibitor
Waldenström Macroglobulinaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05800015
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels (
R3767-ONC-2236
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05552976
Haem
Phase 3
Recruiting
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-2
cereblon E3 ligase modulator
glucocorticoid
proteasome inhibitor
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.9016 - Dunedin - Dunedin Hospital
NCT05514054
Curative
Phase 3
Recruiting
EMBER-4
: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
selective estrogen receptor degrader
Breast cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4215 - Southport - Gold Coast University Hospital
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT05512390
Haem
Phase 1
Recruiting
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies (
M22-716
)
anti-CD19 antibody-drug conjugate,glucocorticoid receptor modulator
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05501886
Advanced
Phase 3
Recruiting
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy (
VIKTORIA-1
)
CDK4/6 inhibitor
pan-PI3K/mTORC1/mTORC2 inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3199 - Frankston - Peninsula Health Frankston Hospital (COMPLETED)
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast Private Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Hollywood Private Hospital
NCT05259839
Haem
Phase 1
Recruiting
A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma (
2023-506871-88-00--M22-947
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05253651
Advanced
Phase 3
Recruiting
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer (
MOUNTAINEER-03
)
ERBB2 inhibitor,third generation
anti-EGFR monoclonal antibody
anti-ERBB2 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT05208944
Advanced
Phase 2
Recruiting
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) (
THIO-101
)
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne (SUSPENDED)
QLD
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (SUSPENDED)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (SUSPENDED)
NCT05150457
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors (
BNA035-101
)
bispecific EGFR/4-1BB antibody
Solid tumour
NSW
2217 - Kogarah - St George Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4217 - Benowa - Pindara Private Hospital
NCT05006716
Haem
Phase 1
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies (
CaDAnCe-101
)
BTK PROTAC degrader
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
Waldenström Macroglobulinemia
NSW
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04973605
Haem
Phase 1
Recruiting
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) (
2023-507751-30-00--BGB-11417-105
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
ACT
2605 - Garran - The Canberra Hospital
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04771130
Haem
Phase 1
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
2021-003285-12--BGB-11417-103
)
Bcl2 inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04643002
Haem
Phase 1
Recruiting
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol (
U1111-1244-2598--ACT16482
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
NCT04534205
Advanced
Phase 2 / Phase 3
Recruiting
An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (
AHEAD-MERIT
)
anti-PD-1 monoclonal antibody
vaccine therapy,HPV-E6/HPV-E7-targeting
Head and neck cancer
Head and neck squamous cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2500 - Wollongong - Wollongong Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital (WITHDRAWN)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (WITHDRAWN)
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT04419649
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (
KER050-MD-201
)
modified ActRIIA ligand trap protein
Myelodysplastic syndrome
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03537482
Advanced
Phase 1
Recruiting
A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies (
APG2575-001
)
Bcl2 inhibitor
Haematological malignancy
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
NCT03486873
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (
3475-587
)
anti-PD-1 monoclonal antibody
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
2060 - North Sydney - Mater Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03175224
Advanced
Phase 2
Recruiting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (
SPARTA
)
MET inhibitor,type 1
Cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Glioblastoma
Kidney cancer
Lung cancer
MET:alteration
MET:fusion
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
Thyroid cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT02468024
Radonc
Phase 3
Recruiting
JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The
STABLE-MATES
Trial
radiotherapy
Non-small cell lung cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (43)
Recruitment Country and State
VIC (42)
NSW (35)
QLD (24)
WA (23)
SA (14)
NZ (9)
ACT (3)
TAS (2)
NT (1)
Phase
Phase 1 (12)
Phase 1 / Phase 2 (2)
Phase 2 (7)
Phase 2 / Phase 3 (2)
Phase 3 (20)
Trial Type
Advanced (21)
Haem (16)
Radonc (3)
Curative (3)
Cancer Therapy Class
PD-1/PD-L1
30%
PD-1
28%
cereblon
14%
Bcl2
12%
CD38
9%
proteasome
9%
GPRC5D
7%
EGFR
7%
LAG3
7%
ER
7%
oestrogen axis
7%
Trop2
5%
ERBB2
5%
PARP
5%
PD-L1
5%
CDK4
5%
CDK6
5%
BTK
5%
VEGF
5%
CD20
2%
B7H3
2%
PSMA∕STEAP1
2%
CS1
2%
XPO1
2%
IDH1
2%
IDH1 R132
2%
KRAS
2%
KRAS G12C
2%
CTLA4
2%
CD19
2%
PI3K
2%
PI3K alpha
2%
mTOR
2%
mTORC1
2%
mTORC2
2%
BCMA
2%
4-1BB
2%
CCR8
2%
DNA methyltransferase
2%
CD47
2%
ROCK2
2%
TGF-beta
2%
HPV-E6
2%
HPV-E7
2%
MET
2%
Facility
3065 - Fitzroy - St Vincent's Hospital Melbourne (43)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (13)
3004 - Melbourne, Southbank - Alfred Health (10)
3168 - Clayton - Monash Medical Centre (10)
4102 - Woolloongabba - Princess Alexandra Hospital (9)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (9)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (9)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (9)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (8)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (7)
3000 - Melbourne - Peter MacCallum Cancer Centre (7)
2050 - Camperdown - Chris O'Brien Lifehouse (7)
2500 - Wollongong - Wollongong Hospital (7)
2170 - Liverpool - Liverpool Hospital (7)
2217 - Kogarah - St George Hospital (6)
3128 - Box Hill - Box Hill Hospital - Eastern Health (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (6)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (5)
2139 - Concord - Concord Repatriation General Hospital (5)
6150 - Murdoch - Fiona Stanley Hospital (5)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (5)
2109 - North Ryde - Macquarie University Hospital (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (4)
3199 - Frankston - Peninsula Health Frankston Hospital (4)
5011 - Woodville South - The Queen Elizabeth Hospital (4)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (4)
5042 - Bedford Park - Flinders Medical Centre (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (4)
3121 - Richmond - Epworth Freemasons Hospital (4)
4575 - Birtinya - Sunshine Coast University Hospital (3)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (3)
4215 - Southport - Gold Coast University Hospital (3)
6009 - Nedlands - One Clinical Research (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (3)
2605 - Garran - The Canberra Hospital (3)
3630 - Shepparton - Goulburn Valley Health (3)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (3)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (3)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (2)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
4740 - Mackay - Mackay Base Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
2200 - Bankstown - Bankstown-Lidcombe Hospital (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
6000 - Perth - Royal Perth Hospital (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
7000 - Hobart - Royal Hobart Hospital (2)
2060 - North Sydney - Mater Hospital (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (2)
4215 - Southport - Tasman Oncology (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
2480 - Lismore - Lismore Base Hospital (1)
6168 - Cooloongup - Rockingham Hospital (1)
2500 - Wollongong - Cancer Care Wollongong (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2576 - Bowral - Southern Highlands Cancer Centre (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
3002 - East Melbourne - Epworth Freemasons (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
3066 - Epping - Northern Hospital (1)
3135 - Ringwood East - Maroondah Hospital (1)
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
4215 - Southport - Gold Coast Private Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
6009 - Nedlands - Hollywood Private Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
2485 - Tweed Heads - The Tweed Hospital (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Thoracic cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Multiple myeloma
Plasma cell disorder
Leukaemia
Gastrointestinal cancer
Gastroesophageal cancer
Upper gastrointestinal cancer
Breast cancer
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Gastric cancer
Gastric carcinoma
Urogenital cancer
Oesophageal cancer
Colorectal cancer
Lower gastrointestinal cancer
Small lymphocytic lymphoma
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Waldenström Macroglobulinaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
High-grade B-cell lymphoma
Colorectal adenocarcinoma
Gastroesophageal junction adenocarcinoma
Head and neck cancer
Head and neck squamous cell carcinoma
Kidney cancer
Pancreatic cancer
Pancreatobiliary cancer
Myelodysplastic syndrome
Myeloproliferative neoplasm
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Gastric adenocarcinoma
HER2-positive gastric cancer
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Bone cancer
Chondrosarcoma
Sarcoma
Mantle cell lymphoma
Marginal zone lymphoma
Breast adenocarcinoma
Cervical cancer
Clear cell renal cell carcinoma
Exocrine pancreatic cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Melanoma
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
Viral-related cancer
Acute myeloid leukaemia
Myelodysplastic/Myeloproliferative disease
Myeloid leukaemia
Colon adenocarcinoma
Endocrine gland cancer
MET:alteration
MET:fusion
Thyroid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy